Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutic products (LBPs) targeting inflammatory and allergic diseases through manipulation of the human microbiome. Their proprietary Precision Symbiotics Platform designs multi-strain microbial consortia to prevent conditions such as atopic dermatitis and food allergy in newborns. Founded as a UCSF spinout, their lead program STMC-103H has received FDA Fast Track Designation.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2024
Sep 2020
Jun 2020
Feb 2019
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
